Search
Cirtuvivint
go.drugbank.com/drugs/DB17269InvestigationalCirtuvivint is a first-in-class CDC-like kinase (CLK) inhibitor.
Disufenton
go.drugbank.com/drugs/DB17298InvestigationalCategories: Compounds used in a research, industrial, or household settingNC-6300
go.drugbank.com/drugs/DB17341ExperimentalNC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.
Trimethyltetradecylammonium
go.drugbank.com/drugs/DB17342ExperimentalCategories: Compounds used in a research, industrial, or household settingOcaratuzumab
go.drugbank.com/drugs/DB17359InvestigationalOcaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.
Synonyms: Immunoglobulin G1, anti-(human B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, membrane-spanning 4-domains subfamily A member 1))LioCyx-M004
go.drugbank.com/drugs/DB17368InvestigationalLioCyx-M004 are autologous T cells transduced with a retroviral vector encoding a hepatitis B virus antigen-specific T cell receptor.
TBX-3400
go.drugbank.com/drugs/DB17370InvestigationalTBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.
Zanolimumab
go.drugbank.com/drugs/DB17376InvestigationalZanolimumab is a fully human monoclonal antibody directed against CD4.
MVR-T3011
go.drugbank.com/drugs/DB17378InvestigationalMVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigationalNadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). … [A255106,L44381] Nadofaragene firadenovec also has a manageable adverse event profile. Compared to [pembrolizumab], a smaller proportion of patients experienced grade 3-4 adverse events (4% vs 12.7%).